SPP Record Date Clarification
Released
Released
Announcement PDF
SPP Record Date Clarification
Melbourne, Australia; 22 September 2014: Starpharma Holdings Limited (ASX: SPL;
OTCQX:SPHRY) provides the following clarification to the record date for the Share
Purchase Plan (“SPP”) outlined in today’s announcement regarding the completion of the
equity placement and follow on SPP.
The correct SPP record date is 7:00pm (Melbourne time) on 19 September 2014, being the
last business day before the SPP was announced.
The opening date of the SPP remains as Monday 29 September 2014.
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY), located in Melbourne Australia, is an ASX 300 company and is a
world leader in the development of dendrimer products for pharmaceutical, life science and other applications.
Starpharma’s underlying technology is built around dendrimers – a type of synthetic nanoscale polymer that is highly regular
in size and structure and well suited to pharmaceutical and medical uses. Starpharma has three core development
programs: VivaGel® portfolio, drug delivery, and agrochemicals with the Company developing a number of products
internally and others via commercial partnerships.
Starpharma’s lead products are based on VivaGel® (SPL7013, astodrimer sodium), a proprietary dendrimer which is a
potent microbicidal agent. VivaGel® formulated as a water based gel and delivered vaginally is under clinical development
for the management and prevention of bacterial vaginosis (BV). Starpharma has also signed separate licence agreements
with Ansell Limited (ASX:ANN) and Okamoto Industries. Inc., (TSE: JP3192800005) to market a value-added, VivaGel®condom. The VivaGel® condom has received Conformity Assessment Certification from the TGA in Australia and marketing
approval in Japan. Okamoto is the market leader for condoms sold in Japan, which is the world’s second largest condom
market. Ansell manufactures and sells leading condom brands worldwide, including Lifestyles®, ZERO® and SKYN®. Ansell
intends to market the VivaGel® condom under the LifeStyles® Dual Protect™ brand name.
In the wider pharmaceutical and life science fields, Starpharma has both partnered and internal programs in Drug Delivery.
Drug Delivery partners include GSK, Lilly and AstraZeneca. A number of dendrimer-enhanced, or DEP™ versions of
existing drugs are under development. The most advanced of these is DEP™docetaxel, a dendrimer-enhanced version of
docetaxel (Taxotere®) which is in clinical development. In preclinical studies DEP™ docetaxel has shown significant tumourtargeting and superior anti-cancer effects across a range of important cancer types including breast, prostate, lung and
ovarian tumour, when compared to Taxotere® (docetaxel).
In agrochemicals Starpharma has a series of partnerships with leading industry players including global leader Adama
(formerly Makhteshim Agan) as well as internal programs including an enhanced version of glyphosate (the active ingredient
in Roundup®).
Media:
Buchan Consulting
Gabriella Hold
Tel: +61 3 9866 4722
ghold@buchanwe.com.au
Starpharma:
Dr Jackie Fairley, Chief Executive Officer
Nigel Baade, CFO and Company Secretary
+61 3 8532 2704
investor.relations@starpharma.com
www.starpharma.com
Rebecca Wilson
Mob: +61 417 382 391
rwilson@buchanwe.com.au
Forward Looking Statements
This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of
forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”,
“targeting”, “aiming”, “set to”, “potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or
similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of
product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause
actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.
There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s and other authorities’ requirements regarding
any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for
sale in any market or that they will reach any particular level of sales. In particular, management’s expectations regarding the approval
and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional
analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain
or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public
pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial
results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove
incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is
providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements
contained in this document as a result of new information, future events or developments or otherwise.
Page 2 of 2
Share your feedback
Discover